AORT NYSE
Credit Risk of going bust: higher than 60% of companies Debt: 26.7% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.73 (down 97%), Artivion, Inc. would be worth roughly what it owes.
Total debt $408.0M against a stock market value of $1.12B.
Distance to default 4.25 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $181.7M (short-term plus half of long-term), stock volatility 51.8%; Altman Z 1.81. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Kennesaw, GA 30144
US
Artivion Inc. is a global company that develops, produces, and supplies medical devices and implantable human tissues. Its product range includes BioGlue, a polymer derived from bovine blood protein combined with a cross-linking agent, utilized in cardiac, vascular, neurological, and pulmonary surgical applications. The company also offers heart preservation services and the PhotoFix bovine pericardial patch, in addition to E-vita Open Plus and E-vita Open Neo devices. For the treatment of aortic vascular conditions, Artivion provides specialized stent graft systems. These include E-xtra design engineering systems for aortic vascular diseases, E-nside as an off-the-shelf solution for thoraco-abdominal disease, E-vita THORACIC 3G for endovascular repair of thoracic aortic aneurysms, E-nya for minimally invasive repair of descending aorta lesions, and the E-tegra system for abdominal aortic aneurysms. Furthermore, its offerings address peripheral and renal artery treatments with the E-ventus BX balloon-expandable stent graft and the E-liac system for aneurysmal iliac arteries and their side branches. The company's diverse portfolio extends to synthetic vascular grafts for use in open aortic and peripheral vascular surgeries, PerClot (an absorbable powdered hemostat for surgical procedures), and cardiac laser therapy products for angina management. Preservation services include CryoVein for femoral veins and CryoArtery for femoral arteries. Artivion also manufactures On-X prosthetic aortic and mitral heart valves, along with the On-X ascending aortic prosthesis. Supplementary devices feature CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures designed for mitral chordal replacement, as well as ascyrus medical dissection stents. Beyond products, the company offers pyrolytic carbon coating services to other medical device manufacturers. Artivion Inc. serves a broad client base, including physicians, hospitals, other healthcare facilities, and specialists such as cardiac, vascular, thoracic, and general surgeons. Established in 1984 and headquartered in Kennesaw, Georgia, the company adopted the name Artivion Inc. in January 2022, having previously operated as CryoLife, Inc.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| GREEN ANDREW M | S-Sale | 11,480 | $24.97 | 2026-09-10 |
| GREEN ANDREW M | S-Sale | 1,493 | $26.02 | 2026-09-03 |
| GREEN ANDREW M | S-Sale | 6,510 | $27.27 | 2026-09-02 |
| Mackin James P | S-Sale | 70,000 | $28.95 | 2026-08-19 |
| GREEN ANDREW M | S-Sale | 616 | $28.55 | 2026-08-14 |